Vontobel Holding Ltd. Bio Atla, Inc. Transaction History

Vontobel Holding Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jun 03, 2024	SELL	$1.27 - $3.18 $11,598 - $29,042	-9,133 Reduced 1.28%	706,062 $1.74 Million
Q4 2023 Jan 29, 2024	SELL	$1.27 - $3.18 $11,598 - $29,042	-9,133 Reduced 1.28%	706,062 $1.74 Million
Q3 2023 Jun 03, 2024	BUY	$1.7 - $3.07 $254,224 - $459,100	149,544 Added 26.44%	715,195 $1.22 Million
Q3 2023 Oct 10, 2023	BUY	$1.7 - $3.07 $254,224 - $459,100	149,544 Added 26.44%	715,195 $1.22 Million
Q2 2023 Jun 03, 2024	BUY	$2.83 - $3.87 $38,230 - $52,279	13,509 Added 2.45%	565,651 $1.7 Million
Q2 2023 Jul 24, 2023	BUY	$2.83 - $3.87 $38,230 - $52,279	13,509 Added 2.45%	565,651 $1.7 Million
Q1 2023 Jun 03, 2024	BUY	$2.3 - $8.25 $1.27 Million - $4.56 Million	552,142 New	552,142 $1.48 Million
Q1 2023 Apr 12, 2023	BUY	$2.3 - $8.25 $930,844 - $3.34 Million	404,715 Added 274.52%	552,142 $1.48 Million
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $927,315 - $1.62 Million	147,427 New	147,427 $1.22 Million

22.1M

10.7K

7.4K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $59.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.